New CDC guidance says fully vaccinated people don’t need to...Leer más
Broad variation in neutralizing antibodies in SARS-CoV-2-convalescent individuals.
∼3% individuals showed a potent antibody response with SARS-CoV-1 cross-reactivity.
Older age, symptomatic and severe disease predict higher SARS-CoV-2 neutralization.
Serum and IgG neutralization half-lives were 14.7 and 31.4 weeks respectively.
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2-neutralization, with these ‘elite neutralizers’ also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity and gender as key factors predicting SARS-CoV-2 neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a stable long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19.
Créditos: Comité científico Covid